• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcemArchiveHomepageTES HomepageSubscriptionsSubmissionAbout
J Clin Endocrinol Metab. Mar 2008; 93(3): 823–831.
Published online Dec 28, 2007. doi:  10.1210/jc.2007-1559
PMCID: PMC2266949

Anastrozole Increases Predicted Adult Height of Short Adolescent Males Treated with Growth Hormone: A Randomized, Placebo-Controlled, Multicenter Trial for One to Three Years


Context: The process of epiphyseal fusion during puberty is regulated by estrogen, even in males.

Objective: Our objective was to investigate whether anastrozole, a potent aromatase inhibitor, could delay bone age acceleration and increase predicted adult height in adolescent boys with GH deficiency.

Methods: Fifty-two adolescent males with GH deficiency treated with GH were randomized to cotreatment with anastrozole or placebo daily for up to 36 months.

Results: Fifty subjects completed 12 months, 41 completed 24 months, and 28 completed 36 months. Linear growth was comparable between groups; however, there was a significantly slower increase in bone age advancement from baseline in the anastrozole group vs. placebo group after 2 yr (+1.8 ± 0.1 vs. +2.7 ± 0.1 yr, P < 0.0001) and after 3 yr (+2.5 ± 0.2 vs. +4.1 ± 0.1 yr, P < 0.0001). This resulted in a net increase in predicted adult height of +4.5 ± 1.2 cm in the anastrozole group at 24 months and +6.7 ± 1.4 cm at 36 months as compared with a 1-cm gain at both time points in the placebo group. Estradiol and estrone concentrations increased less in the anastrozole group compared with placebo group. All boys on the aromatase inhibitor had normal tempo of virilization. Safety data, including glucose, and plasma lipid concentrations were comparable between groups.

Conclusions: Anastrozole increases adult height potential of adolescent boys on GH therapy while maintaining normal pubertal progression after 2–3 yr. This treatment offers an alternative in promoting growth in GH-deficient boys in puberty. Long-term follow up is needed to elucidate fully the safety and efficacy of this approach.

A number of strategies have evolved to increase height potential in GH-deficient children who are in puberty, such as using high-dose GH therapy (1) or GnRH analogs in addition to GH (2,3,4,5). The latter strategy has also been used in non-GH-deficient children, with mixed results (6,7,8). The consequences of gonadal suppression regarding bone accretion/bone density and the psychological impact of suppressing physiological puberty in an already short child have not been fully studied to date.

Studies of male patients with mutations in the estrogen receptor gene (9) or in the aromatase enzyme gene (10,11) as well as animal data (12) have shown that estrogen, in both females and males, is a principal regulator of epiphyseal fusion. Hence, a third strategy has evolved with more selective suppression of either estrogen production or estrogen action in puberty in those children who are very short. Administering 10 wk of the aromatase inhibitor anastrozole, which blocks conversion of Δ4-androstenedione to estrone and testosterone to estradiol, in young males, we observed no negative effects of estrogen suppression on a host of metabolic measures despite a 50% reduction in circulating estradiol concentrations (13). This is in sharp contrast to the deleterious effects of GnRH analog therapy described by us in males (14,15).

Data in boys treated with letrozole (another aromatase inhibitor) and testosterone (16) and results from a 2-yr trial using letrozole as monotherapy in boys with idiopathic short stature (17) also suggest that aromatase blockers may be a suitable alternative to promote growth in short boys in puberty. We designed this double-blind, randomized, placebo-controlled clinical trial to investigate whether treatment with a selective and potent aromatase inhibitor (anastrozole) delays the rate of bone age maturation and whether it increases adult height potential in GH-deficient adolescent boys also treated with GH. Secondary aims included measuring changes in growth velocity and height sd score adjusted for bone age, as well as changes in pubertal hormones, bone mineral density (BMD), and body composition. A thorough assessment of safety was conducted as well.

Subjects and Methods

Studies were approved by the Nemours Clinical Research Review Committee and the Institutional Review Boards of all seven participating sites. This was an original, investigator-initiated trial registered at www.clinicaltrials.gov, identifier NCT00133354.

Study subjects

Fifty-two boys with GH deficiency were recruited after informed written consent from their parents and them.

Inclusion criteria

GH deficiency was defined as evidence of either 1) short stature (>2 sd below average) or 2) significant growth deceleration (growth velocity ≤ 25% of corresponding chronological age population) and 3) peak GH responses to two pharmacological stimuli of no more than 10 ng/ml. They had to be on stable daily doses of GH for at least 6 months before, using average doses of about 0.3 mg/kg·wk. Subjects had to be in puberty [genital Tanner stage > II (>4 ml testicular volume)] and had to have residual height potential (bone age > 11.5 yr and <15 yr) at study entry.

Exclusion criteria

Subjects were excluded if they participated in other trials involving hormone therapy within 6 months, had chronic illnesses requiring long-term medication that impair growth, or had any hereditary disease or scoliosis at study entry.

Study protocol

A physical examination, including pubertal Tanner staging, accurate height measurement, blood tests, and a bone age x-ray were obtained at screening. Once determined eligible, treatment with anastrozole or placebo tablets was determined by a randomization schedule prepared by AstraZeneca, who provided the study drug and placebo tablets for the trial. Investigators, staff, and patients were unaware of the randomization codes until completion of the trial and data analysis. Dual-energy x-ray absorptiometry (DXA) was performed before initiation of study drug whenever possible but was not required. After the baseline visit, patients took 1 mg anastrozole (Arimidex) or placebo daily in addition to daily GH. Patients were followed at 3-month intervals during routine clinic visits, and blood samples and accurate anthropometric measurements were repeated each time. GH doses were titrated based on growth and body weight as needed. Left hand and wrist x-rays were obtained at 0, 12, 24, and 36 months for bone age determinations, and DXA was repeated after 24 and 36 months whenever possible. The study was continued until 36 months or until completion of linear growth, whichever happened sooner, the latter defined as the achievement of a bone age of at least 16 yr and a growth velocity of less than 2 cm/yr. Patients who voluntarily dropped out of the study were studied at termination with repeat height and weight measurements, blood tests, bone age, and DXA.


Blood concentrations of IGF-I, testosterone, lipids, glucose, estradiol, and osteocalcin were measured at 6-month intervals and complete blood count and chemistry profile with liver enzymes first every 3–6 months. Hormone concentrations were measured by RIA using commercially available Diagnostic Systems Laboratories kits (Webster, TX) at the study’s core laboratory at Nemours Children’s Clinic-Jacksonville. The intraassay coefficients of variation were 1.5% for IGF-I, 8.1% for testosterone, and 5.3% for osteocalcin. Estradiol and estrone assays were run at Dr. Ravinder Singh’s laboratory at the Mayo Clinic (Rochester, MN), using samples solvent extracted by liquid chromatography (LC) and subjected to tandem mass spectrometry (MS/MS) as previously described (18). The lower limit of sensitivity was 2 pg/ml with an intra assay coefficient of variation of about 4–20% in the lowest ranges.

Bone age and DXA readings

Bone age determinations were performed at Fels Institute (Yellow Springs, OH) by one single experienced reader blinded to the treatment arm. Predicted adult heights were estimated based on the Bayley-Pinneau table (19). DXA scans of the lumbar spine were performed using either Hologic (Waltham, MA) or Lunar instruments (Minster, OH).

Body composition

Whenever possible, body composition was assessed using the DXA software; however, not all participating centers had access to this, and it was considered an optional criteria for study participation. Because body composition was not a principal aim of these studies, in patients without DXA, those data were obtained through the sum of skinfold thicknesses (20). In nonobese individuals, the assessment of body composition correlates well with those obtained by DXA (21). This aim was considered exploratory.


Anastrozole (Arimidex) (1-mg tablet) and placebo tablets were provided by AstraZeneca (Wilmington, DE) and dispensed for daily dosing under protocol using the principal investigator’s FDA IND number. All unused and empty vials were returned to the clinical centers for drug accountability. Recombinant human GH (somatropin) was provided to the study subjects as Nutropin, Nutropin AQ, or Saizen by generous drug-supply grants from Genentech (South San Francisco, CA) and EMD Serono (Rockland, MA), respectively. Those subjects that did not wish to switch brands were continued on their commercially prescribed somatropin products. The daily dose used throughout the study was about 50 μg/kg·d (or 0.35 mg/kg·wk).

Safety monitoring

A data safety management board composed of two pediatric endocrinologists and another pediatric subspecialist, not associated with the conduct of the studies, was established since the protocol’s inception, and all data, results and safety, were reported to them quarterly. Side effects were monitored, and all illnesses reported (gastroenteritis, respiratory, allergies, etc.) were recorded as adverse events. Any hospitalizations, surgery, or other significant events were recorded as serious adverse events and reported to the institutional review boards and data safety management board.

Statistical analysis

The primary endpoint of this trial was the change in predicted adult height between baseline and the end of therapy. The primary endpoint was compared between the treatment groups using two-sample t test. The analyses were not adjusted for the effect of trial center or for any interaction between covariates and the treatment group. Secondary endpoints included changes in bone age, growth velocity, height SDS adjusted for bone age, and changes in hormone concentrations. Tolerability and safety endpoints included adverse events, withdrawals, and laboratory data including glucose, lipid panel, and liver profile concentrations. By study design, data were unblinded to one single individual and analyzed after all available subjects completed 24 months of treatment. Neither the investigators nor participating subjects had any knowledge of the treatment arms. The protocol was continued in all available subjects through 36 months. Afterward, whenever possible, subjects are being followed and measured at each site until completion of near adult height. Those measurements are ongoing.

Subjects were analyzed on the basis of the treatment received and those without post-baseline measurements were excluded from the analyses of that variable. The analyses of endpoints at specific time points during the study included only patients with measurements available at that time point (and baseline, for change from baseline variables). No adjustments were made to any of the analyses for multiple testing, because some of the endpoints may be relatively well correlated with one another. The results of the analyses are presented using the simple means for the anastrozole and placebo groups along with the corresponding sem and the two-sided t test P value for treatment comparison. The analysis was carried out using SAS software. Significance was established as P < 0.05.


Fifty-two subjects were recruited for participation, with clinical characteristics shown in Table 11.. All but one of the subjects had isolated idiopathic GH deficiency; one had GH and TSH deficiency, the latter well replaced. Of the 52 subjects, 50 completed 12 months, 41 completed 24 months, and 28 completed 36 months.

Table 1
Clinical characteristics of study subjects at baseline

Pubertal and bone hormones (Fig. 11)

Figure 1
Changes in testosterone, estradiol, estrone, IGF-I, and osteocalcin concentrations vs. baseline in the anastrozole (AN, solid lines) vs. placebo (PL, broken lines) groups. *, P = 0.01 for testosterone; *, P < 0.001 for ...

Serum testosterone concentrations increased during the 3 yr in both groups with the analyte concentrations for the whole groups at 0, 12, 24, and 36 months: anastrozole, 215 ± 35, 667 ± 71, 628 ± 71, and 510 ± 63 ng/dl; placebo, 162 ± 30, 416 ± 51, 570 ± 57, and 338 ± 31 ng/dl, respectively (P = 0.01 between groups at 12 months). When changes from baseline were analyzed, there was a greater increase in testosterone at 12 months in the anastrozole than the placebo group (+452 ± 67 vs. 254 ± 39 ng/dl, P = 0.01); however, this difference was not significant at 24 months (anastrozole, +445 ± 73 ng/dl; placebo, +450 ± 57 ng/dl, P = 0.74) or at 36 months (anastrozole,+325 ± 54 ng/dl; placebo, 257 ± 24 ng/dl, P = 0.25) (Fig. 11).

Estradiol concentrations were stable in the anastrozole group, whereas they increased in the placebo group at 0, 12, 24, and 36 months: anastrozole, 9.6 ± 1.1, 6.7 ± 0.9, 6.6 ± 1.0, and 8.1 ± 2.0 pg/ml; placebo, 7.5 ± 1.2, 11.0 ± 1.3, 16.2 ± 1.1, and 16.8 ± 1.7 pg/ml (P < 0.01 between groups at all time points except baseline, not significant). Estrone concentrations followed a similar pattern at 0, 12, 24, and 36 months: anastrozole, 14.0 ± 1.5, 4.7 ± 1.1, 6.0 ± 1.2, and 8.1 ± 2.7 pg/ml; placebo, 12.2 ± 1.4, 14.2 ± 1.7, 18.1 ± 1.5, and 18.5 ± 1.3 pg/ml (P < 0.01 between groups at all time points except baseline, not significant). Analysis of changes in plasma estradiol concentrations vs. baseline showed decreased levels in the anastrozole vs. placebo group at 12 months (anastrozole, −2.8 ± 1.1 pg/ml vs. placebo, +4.1 ± 0.8 pg/ml, P = 0.0001), at 24 months (anastrozole, −1.9 ± 1.5 pg/ml vs. placebo, +9.5 ± 1.4 pg/ml, P < 10−5), and at 36 months (anastrozole. −0.2 ± 2.2 pg/ml vs. placebo, +12.5 ± 1.5 pg/ml, P = 0.0002. Differences in estrone concentrations vs. baseline followed the same trends of the estradiol concentrations at 12 months (anastrozole, −9.1 ± 1.8 pg/ml vs. placebo, +3.7 ± 1.4 pg/ml, P = 1.2 x10−5), at 24 months (anastrozole, −5.3 ± 2.3 pg/ml vs. placebo, +6.6 ± 1.6 pg/ml, P = 1.7 x10−5), and at 36 months (anastrozole, −4.3 ± 2.6 pg/ml vs. placebo, +8.3 ± 1.9 pg/ml, P = 0.0001) (Fig. 11).

IGF-I concentrations were similar at baseline and increased comparably in both groups throughout the study at 0, 12, 24, and 36 months: anastrozole, 737 ± 64, 935 ± 79, 986 ± 107, and 879 ± 112 ng/dl; placebo, 812 ± 56, 1020 ± 80, 1059 ± 93 933 ± 76 ng/dl (P value not significant). There was no difference in the increase from baseline between the groups (Fig. 11).). The total group concentrations of osteocalcin were remarkably stable during the entire study period at 0, 12, 24, and 36 months: anastrozole, 54 ± 2, 55 ± 2, 53 ± 2, and 52 ± 4 ng/ml; placebo, 58 ± 3, 51 ± 2, 51 ± 3, 46 ± 3 ng/ml (P value not significant). There was no difference in changes in osteocalcin concentrations vs. baseline between the groups (Fig. 11).

Lipid and glucose concentrations (Table 22)

Table 2
Changes in fasting lipids and glucose concentrations vs. baseline

Plasma lipids and fasting glucose concentrations were normal with no significant differences in either the anastrozole or the placebo group over time in analyte concentrations in the total cohort (data not shown). When comparing the changes at each time point vs. baseline, there were only differences between the two groups at 12 months, with a statistically greater drop in high-density lipoprotein cholesterol in the anastrozole group at 12 months compared with the placebo group (−18 ± 4 vs.−1 ± 4 mg/dl, P < 0.002) but a greater drop in total cholesterol also in the anastrozole group compared with the placebo group (−6 ± 2 vs.−2 ± 2 mg/dl, P < 0.05). There were no differences in the changes in these concentrations compared with baseline between the two groups at any other time point.

Anthropometry and body composition (Table 33)

Table 3
Anthropometric, body composition, and bone mineral density changes vs. baseline

There were no significant differences in height between the two groups as a whole throughout the study period at 0, 12, 24, and 36 months: anastrozole, 149.7 ± 1.6, 157.7 ± 1.5, 162.9 ± 1.4, and 165.8 ± 1.3 cm; placebo, 151.9 ± 1.2, 160.6 ± 1.3, 166.6 ± 1.4, and 167.8 ± 1.8 cm (P value not significant). Analysis of the changes in growth parameters vs. baseline showed that growth velocity, as expected, decreased in both groups over time; however, the decrease vs. baseline was more significant in the placebo group at 36 months (P = 0.04). Changes in fat-free mass and percent fat mass from baseline were not different between the groups (Table 33).). There were no differences in BMI vs. baseline between groups.

Bone age and predicted adult height

The tempo of bone age acceleration was significantly different between the groups (anastrozole, 13.7 ± 0.2 (baseline), 14.7 ± 0.2 (12 months), 15.4 ± 0.2 (24 months), and 15.9 ± 0.3 yr (36 months); placebo, 13.4 ± 0.2 (baseline), 14.8 ± 0.2 (12 months), 16.0 ± 0.2 (24 months), and 17.2 ± 0.3 yr (36 months). When the same subjects were compared at the same time points, there were significant differences between groups apparent after 24 months: anastrozole vs. placebo at 12 months, +1.1 ± 0.1 vs. +1.4 ± 0.1 yr, P = 0.08; at 24 months, + 1.8 ± 0.1 vs. +2.7 ± 0.1 yr, P < 0.0001; and at 36 months, +2.5 ± 0.2 vs. +4.1 ± 0.1 yr, P < 0.0001 (Fig. 22).). There was a corresponding improvement in the gain in height sd score (SDS) adjusted for bone age at 24 and 36 months in the anastrozole group compared with the placebo group with net gains at 12 months of +0.22 ± 0.07 vs. +0.03 ± 0.13 SDS (P = 0.2); at 24 months, +0.52 ± 0.12 vs. +0.04 ± 0.13 SDS (P = 0.009); and at 36 months, +0.77 ± 0.16 vs.−0.10 ± 0.16 SDS (P = 0.0009) in the anastrozole and placebo groups, respectively (Fig. 33).). These differences translated into greater gains in predicted adult height from baseline in the anastrozole group compared with the placebo group in paired analysis: anastrozole vs. placebo: at 12 months, +1.3 ± 0.7 vs. +0.3 ± 1.0 cm (P = 0.4); at 24 months, +4.5 ± 1.2 vs. +1.1 ± 1.1 cm (P = 0.04); and at 36 months, +6.7 ± 1.4 vs. +1.0 ± 1.1 cm (P = 0.004) (Fig. 44).). For the primary, intent-to-treat analysis of change in predicted adult height at the end of therapy (i.e. including the last measurements for a subject withdrawing early), the P value for treatment comparison was 0.03.

Figure 2
Changes in bone age compared with baseline at 12, 24, and 36 months in the anastrozole and placebo groups. Insets indicate mean change from baseline. *, P value is significant vs. placebo group at 24 and 36 months (P < 0.001 both times). ...
Figure 3
Change from baseline in SDS adjusted for bone age in the anastroloze and placebo groups at 12, 24, and 36 months. *, P value is significant vs. placebo group at 24 (P = 0.009) and 36 months (P = 0.0009).
Figure 4
Changes in predicted adult height based on Bayley Pinneau tables compared with baseline in the anastrozole and placebo groups. *, P value is significant vs. placebo group at 24 (P = 0.04) and 36 months (P = 0.004).

Pubertal changes

The pace of pubertal progression was similar between the groups as measured by changes in testosterone concentrations and testicular volumes. On average, right and left testes increased in volume from about 10–25 ml bilaterally in both groups. The anastrozole and placebo groups both were reported at Tanner stage V genital and pubic hair at the study completion.

BMD (Table 33)

DXA analysis was not a principal aim of the study, and it was performed mostly as a safety measure; hence, subjects were not denied entry into the study because of lack of available DXA. We had DXAs on 39 of 52 subjects available at baseline, 28 of 41 at 24 months, and 14 of 28 at 36 months. There were no significant differences between the groups in lumbar spine BMD (data not shown). Paired analysis of the available subjects showed there was a statistical difference in lumbar spine BMD Z score between 24 months and baseline (P = 0.02), whereas there was no significant differences between the groups in gain in Z score compared with baseline at 36 months (P = 0.2).


Anastrozole was well tolerated and largely free of side effects. There were no differences between the groups on complete blood counts, urinalysis, or liver profiles. The frequency for adverse events (head and neck, respiratory, gastrointestinal, genitourinary, and musculoskeletal) was similar in both groups. There were seven serious adverse events; four were in the same subject who had repeated episodes of cyclical vomiting, diagnosed after extensive workup in gastroenterology as psychogenic emesis. Another fractured an arm after severe sports trauma, one had an elective forearm bone surgery from previous trauma before the study, and the last one had a septic arthritis from a presumed focus of sinus infection. All reported serious adverse events were in the anastrozole group, none were considered related to the study medication by the investigators, and in all, anastrozole was quickly resumed after hospital discharge.

Long-term follow up

Nine subjects withdrew from the study because of either satisfaction with their achieved height or psychosocial issues at home or school, or they got tired of taking medications. Five subjects were discontinued by the investigators because of poor drug compliance or were lost to follow-up. Whenever possible, subjects are being followed to measure their final adult height; these measurements are ongoing.


One of the challenging issues in dealing with short children in puberty is the limited time available to increase linear growth during concomitant and rapid epiphyseal fusion. The use of a potent aromatase inhibitor, anastrozole, resulted in a significant delay in the tempo of bone age acceleration compared with placebo in adolescent boys with GH deficiency who were also treated with GH. This slowing of epiphyseal fusion caused by estrogen blockade resulted in a significant net gain in predicted adult height, as calculated based on bone age, of +4.5 ± 1.2 cm and +6.7 ± 1.4 cm after 2 and 3 yr, respectively, compared with +1 cm at both time points in the placebo group. This translated into a net gain from baseline in height SDS adjusted for bone age in the anastrozole vs. the placebo group. We intentionally targeted an age range in which a natural deceleration of growth occurs after peak growth velocity. The drop in growth velocity during the course of these studies was also greater in the placebo group than in the anastrozole group at 36 months.

The effects of estrogen blockade are remarkable and cannot be fully appreciated after only 1 yr of treatment but are particularly evident at 24 months and in those that continued through 36 months. This observed benefit increasing height potential takes at least 2 yr. Comparable results were observed in boys with idiopathic short stature treated for 2 yr with letrozole, another aromatase inhibitor (17). The findings are also similar to the increase in predicted adult height observed after coadministration of the GnRH analog and GH (2) or GH in high doses in adolescents reported previously (1) in which positive results were apparent only after the second year of treatment. This observation that gains in adult height potential take up to 3 yr of treatment to be observed was also shown in low-birth-weight girls treated with the insulin sensitizer metformin reported by Ibáñez et al. (22). The changes in predicted adult height reported here were accompanied by normal progression of puberty, with normal virilization and testicular enlargement, not different from placebo. Testosterone concentrations increased initially more in the anastrozole group than in the placebo group at 12 months but not after continued treatment at 24 and 36 months. The ability of these adolescent boys to continue to virilize while slowing down epiphyseal fusion offers a potentially better alternative to the complete biochemical suppression of the gonadal axis caused by treatment with GnRH analogs.

Bayley Pinneau was the height prediction method used, but all current methods of height prediction can either under- or overestimate ultimate height because the accuracy depends on height gained during the pubertal growth spurt, which is highly variable. It seems clear that there is no best method and that each has its advantages and disadvantages under specific circumstances (23,24,25,26,27,28). In a metaanalysis of 10 studies in children with delayed growth followed to final adult height, the prediction error for the Bayley Pinneau method was approximately +2.4 cm (28), lower than other methods (24). The method used throughout this study was the same for all patients in both groups, using one single observer at the Fels Institute, making comparisons still robust. A recent mathematical model has shown that epiphyseal maturation and sex steroids may be more important determinants of pubertal growth spurt than GH dose (29). Hence, we believe that the effect of aromatase blockade was clinically significant, independent of GH, because the GH dose was controlled in the placebo group.

Plasma IGF-I concentrations were similar between the two groups throughout the study, in contrast to the decrease we and others observed after aromatase blockade in males (13,16,17). This is likely related to coadministration of GH in our experiments. Combining GH and anastrozole treatment might allow for normal pubertal height gain without having to increase the GH dose.

There is at present no consensus on the best estradiol assay to use, and often commercially available assays are not sensitive enough to pick up differences after given interventions. However, using a sensitive LC-MS/MS assay, we observed a significant decline in estradiol and estrone concentrations in the adolescents treated with anastrozole, whereas the placebo group continued to increase their estradiol and estrone levels as they progressed through puberty. These changes are not as marked as the 50% decline in estradiol concentrations after 1 yr of treatment in boys reported by us previously (30) using a highly sensitive recombinant cell bioassay (31). However, the results reported here show marked differences in the concentration changes over time between the two groups, reflecting the significant aromatase blockade caused by the anastrozole. Regardless of plasma estradiol concentrations, suppressing tissue aromatase at the epiphyseal growth plate is most important, and anastrozole can achieve more than 98% tissue aromatase blockade (32,33). When following these patients, measuring estradiol concentrations is only useful if the assay has a very low sensitivity and is properly validated, which most commercial assays are not. The clinician needs to know the sensitivity and limits of the assay used.

Our results on body composition cannot be considered definitive due to the combination of methods used, however they show interesting trends, with comparable increases in fat-free mass accrual and reciprocal decreases in % adiposity. This differs to the observed decrease in lean body mass and increase in % fat mass in healthy young males studied with a GnRH analog (14). It is possible that the lack of difference in body composition between the 2 groups studied here is due in part to the continued use of GH, a potent enhancer of lean body mass accrual in youth (34).

The increase in lumbar BMD was less in the anastrozole group at 24 months but not at 36 months. We acknowledge that correction for body size or height might offer a better estimate of the status of bone health (35,36) and that typically short subjects show even fewer bone abnormalities when areal BMD is corrected for size (37). However, there is presently no adequate normative data for volumetric BMD to compare against in children and no consensus on standards for adjusting BMD for size (38). Osteocalcin concentrations, a measure of bone formation, were similar at all time points between the groups. This contrasts with the significant decrease in measures of bone formation observed in GnRH analog-treated young men (15). Although human estrogen receptor and aromatase knockouts had osteopenia (9,11), when estrogen suppression was short-term, BMD was normal in letrozole-treated boys followed for 2 yr, reported previously (17). Our limited DXA data suggest that for up to 3 yr, timed aromatase blockade given with GH therapy is not detrimental to bone health. However, longitudinal follow-up is still needed.

Most of the boys studied had been on GH an average of about 3 yr before study entry and represent a typical group of GH-treated GH-deficient adolescents in the United States. We intentionally had no cutoff criteria for IGF-I concentrations at the original diagnosis because the variability in IGF-I assays is significant (39,40,41,42). It also depends on nutritional status, making it less useful for diagnosis unless values are severely low. We chose instead to include GH-deficient patients with peak GH responses to two pharmacological stimuli less than 10 ng/ml, a common (although arbitrary) cutoff used to identify patients with GH deficiency. Whether use of aromatase inhibitors in children with even more profound GH deficiency would be beneficial in increasing height potential in puberty awaits further study.

Extensive 3-yr safety data in these boys showed no differences in lipid or glucose concentrations, liver function tests, or adverse event rates between the groups. Anastrozole was well tolerated and safe for up to 3 yr. However, long-term data are still needed and continued surveillance a must as well as careful monitoring of BMD accrual.

Aromatase inhibitors are a class of compounds presently approved for treatment of postmenopausal women with early or metastatic hormone receptor-positive breast cancer. However, this class of drugs has been clinically tested in a variety of other experimental situations to selectively decrease estrogen (43,44,45,46,47,48). Previous studies in boys with constitutional growth delay treated with letrozole and followed to adult height have shown that the reported increase in adult height potential was sustained after drug discontinuation (16,49). Whether or not the observed increase in predicted adult height in our present study in GH-deficient adolescent boys will also translate into taller adult height for the subjects requires long-term follow-up.

In summary, 2–3 yr of aromatase blockade with anastrozole in GH-treated boys caused a significant slowing of the tempo of bone age maturation, resulting in a significant gain in predicted adult height compared with placebo. This was accompanied by normal tempo of virilization, pubertal hormones, IGF-I concentrations, and lipid concentrations, with a strong safety profile. Anastrozole treatment in GH-treated males offers promise and may be a useful choice in the approach to the growth-retarded male in puberty. Long-term follow-up to final adult height is still needed to fully characterize the safety and efficacy of this approach.


We are grateful to the study coordinators at each site; to Shawn Sweeten and Brenda Sager for laboratory assistance; Dr. Ravinder Singh and Sara Duenes at Mayo Clinic Rochester for measurement of estradiol assays by LC-MS/MS; and Sylvia Kyle, librarian. We also greatly appreciate the contribution of the data safety management board, including: Dr. Edward Reiter (Baystate Medical Center, Springfield, MA), Dr. Janet Silverstein (University of Florida College of Medicine, Gainesville, FL), and Dr. Pamela H. Arn (Nemours Children’s Clinic, Jacksonville, FL).


This work was supported by an investigator-initiated research grant from AstraZeneca and drug supply grants from Genentech and EMD Serono. This publication was also made possible by Mayo Clinic Center for Clinical Translational Science Award Grant no. UL1 RR024150 from the National Center for Research Resources, a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research.

Disclosure Statement: N.M. has consulted for AstraZeneca and Genentech and has received lecture fees from Genentech and Serono. N.M. received a research grant from AstraZeneca for the conduct of these studies and drug supply from Genentech and EMD Serono. Authors L.G.d.P., H.Y.H., P.D., I.D.S., K.O.K., K.B., A.M., and R.J.S. have nothing to disclose. R.R. has consulted for Serono and received lecture fees from Lilly and Pfizer.

First Published Online December 28, 2007

Abbreviations: BMD, Bone mineral density; DXA, dual-energy x-ray absorptiometry; LC-MS/MS, liquid chromatography-tandem mass spectrometry; SDS, sd score.


  • Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J 2000 High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab 85:3653–3660 [PubMed]
  • Mericq MV, Eggers M, Avila A, Cutler Jr GB, Cassorla F 2000 Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone- releasing hormone analog: results of a prospective, randomized trial. J Clin Endocrinol Metab 85:569–573 [PubMed]
  • Cassorla F, Mericq V, Eggers M, Avila A, Garcia C, Fuentes A, Rose SR, Cutler GB 1997 Effects of luteinizing hormone-releasing hormone analog-induced pubertal delay in growth hormone (GH)-deficient children treated with GH: preliminary results. J Clin Endocrinol Metab 82:3989–3992 [PubMed]
  • Cara JF, Kreiter ML, Rosenfield RL 1992 Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone. J Pediatr 120:709–715 [PubMed]
  • Reiter EO 2006 A brief review of the addition of gonadotropin-releasing hormone agonists (GnRH-Ag) to growth hormone (GH) treatment of children with idiopathic growth hormone deficiency: previously published studies from America. Mol Cell Endocrinol 254–255:221–225 [PubMed]
  • Pasquino AM, Pucarelli I, Roggini M, Segni M 2000 Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone. J Clin Endocrinol Metab 85:619–622 [PubMed]
  • Balducci R, Toscano V, Mangiantini A, Municchi G, Vaccaro F, Picone S, Di Rito A, Boscherini B 1995 Adult height in short normal adolescent girls treated with GnRHa and GH. J Clin Endocrinol Metab 80:3596–3600 [PubMed]
  • Lanes R, Gunczler P 1998 Final height after combined growth hormone and gonadotropin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty. Clin Endocrinol (Oxf) 49:197–202 [PubMed]
  • Smith EP, Boyd J, Frank GR 1994 Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056–1061 [PubMed]
  • Carani C, Qin K, Simoni M 1997 Effect of testosterone and estradiol in man with aromatase deficiency. N Engl J Med 1337:91–95 [PubMed]
  • Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K 1995 Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80:3689–3698 [PubMed]
  • Gunther DF, Calikoglu AS, Underwood LE 2000 The effects of the estrogen receptor blocker, Faslodex (ICI 182,780), on estrogen-accelerated bone maturation in mice. Pediatr Res 46:269–273 [PubMed]
  • Mauras N, O’Brien KO, Klein KO, Hayes V 2000 Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 85:2370–2377 [PubMed]
  • Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD, Urban RJ 1998 Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength and adiposity. J Clin Endocrinol Metab 83:1886–1892 [PubMed]
  • Mauras N, Hayes V, Yergey AL 1999 Profound hypogonadism has significant negative effects on calcium balance in males: a calcium kinetic study. J Bone Miner Res 14:577–582 [PubMed]
  • Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L 2001 A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomized controlled trial. Lancet 357:1743–1748 [PubMed]
  • Hero M, Norjavaara E, Dunkel L 2005 Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 90:6396–6402 [PubMed]
  • Nelson RE, Grebe SK, OKane DJ, Singh RJ 2004 Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma. Clin Chem 50:373–384 [PubMed]
  • Greulich WW, Pyle SI 1959 Radiographic atlas of skeletal development of the hand and wrist. Stanford, CA: Stanford University Press
  • Durnin JV, Womersley J 1974 Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 32:77–97 [PubMed]
  • Steinberger J, Jacobs DR, Raatz S, Moran A, Hong CP, Sinaiko AR 2005 Comparison of body fatness measurements by BMI and skinfolds vs dual energy x-ray absorptiometry and their relation to cardiovascular risk factors in adolescents. Int J Obes (Lond) 29:1346–1352 [PubMed]
  • Ibáñez L, Valls C, Ong K, Dunger DB, de Zegher F 2006 Metformin therapy during puberty delays menarche, prolongs pubertal growth, and augments adult height: a randomized study in low-birth-weight girls with early-normal onset of puberty. J Clin Endocrinol Metab 91:2068–2073 [PubMed]
  • Zachmann M, Sobradillo B, Frank M, Frisch H, Prader A 1978 Bayley-Pinneau, Roche-Wainer-Thissen, and Tanner height predictions in normal children and in patients with various pathologic conditions. J Pediatr 93:749–755 [PubMed]
  • Bramswig JH, Fasse M, Holthoff ML, von Lengerke HJ, von Petrykowski W, Schellong G 1990 Adult height in boys and girls with untreated short stature and constitutional delay of growth and puberty: accuracy of five different methods of height prediction. J Pediatr 117:886–891 [PubMed]
  • Joss EE, Temperli R, Mullis PE 1992 Adult height in constitutionally tall stature: accuracy of five different height prediction methods. Arch Dis Child 67:1357–1362 [PMC free article] [PubMed]
  • de Waal WJ, Greyn-Fokker MH, Stijnen T, van Gurp EA, Toolens AM, de Munick Keizer-Schrama SM, Aarsen RS, Drop SL 1996 Accuracy of final height prediction and effect of growth-reductive therapy in 362 constitutionally tall children. J Clin Endocrinol Metab 81:1206–1216 [PubMed]
  • Bull RK, Edwards PD, Kemp PM, Fry S, Hughes IA 1999 Bone age assessment: a large scale comparison of the Greulich and Pyle, and Tanner and Whitehouse (TW2) methods. Arch Dis Child 81:172–173 [PMC free article] [PubMed]
  • Hintz RL 2001 Final height prediction in constitutional growth delay. J Pediatr Endocrinol Metab 14 (Suppl 6):1535–1540 [PubMed]
  • Ranke MB, Lindberg A, Martin DD, Bakker B, Wilton P, Albertsson-Wikland K, Cowell CT, Price DA, Reiter EO 2003 The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose. J Clin Endocrinol Metab 88:4748–4753 [PubMed]
  • Mauras N, Welch S, Rini A, Klein KO 2004 An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. J Pediatr Endocrinol Metab 17:1597–1606 [PubMed]
  • Klein KO, Baron J, Colli MJ, McDonell DP, Cutler GB 1994 Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest 94:2475–2480 [PMC free article] [PubMed]
  • Plourde P, Dyroff M, Dukes M 1994 Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 30:103–111 [PubMed]
  • Plourde P, Dyroff M, Dowsett M, Demers L, Yates R, Webster A 1995 Arimidex: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 53:175–179 [PubMed]
  • Mauras N, Haymond H 2005 Are the metabolic effects of GH and IGF-I separable? Growth Horm IGF Res 15:19–27 [PubMed]
  • Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G 1998 Measurement of volumetric bone mineral density accurately determines degree of lumbar undermineralization in children with growth hormone deficiency. J Clin Endocrinol Metab 83:3150–3154 [PubMed]
  • Hogler W, Briody J, Moore B, Lu PW, Cowell CT 2005 Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency. Bone 37:642–650 [PubMed]
  • Fewtrell MS, Gordon I, Biassoni L, Cole TJ 2005 Dual x-ray absorptiometry (DXA) of the lumbar spine in a clinical paediatric setting: does the method of size-adjustment matter? Bone 37:413–419 [PubMed]
  • Lewiecki EM, Binkley N, Bilezikian JP, Kendler DL, Leib ES, Petak SM 2006 Official positions of the International Society for Clinical Densitometry. Osteoporos Int 17:1700–1701 [PubMed]
  • Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML; Endocrine Society’s Clinical Guidelines Subcommittee, Stephens PA 2006 Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 91:1621–1634 [PubMed]
  • Rosenfeld RG, Albertsson-Wikland K, Cassorla F, Frasier SD, Hasegawa Y, Hintz RL, Lafranchi S, Lippe B, Loriaux L, Melmed S, Preece MA, Ranke MB, Reiter EO, Rogol AD, Underwood LE, Werther GA 1995 Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 80:1532–1540 [PubMed]
  • Hilczer M, Smyczynska J, Stawerska R, Lewinski A 2006 Stability of IGF-I concentration despite divergent results of repeated GH stimulating tests indicates poor reproducibility of test results. Endocr Regul 40:37–45 [PubMed]
  • Anckaert E, Schiettecatte J, Vanbesien J, Smitz J, Velkeniers B, De Schepper J 2006 Variability among five different commercial IGF-1 immunoassays in conditions of childhood-onset GH deficiency and GH therapy. Acta Clin Belg 61:335–339 [PubMed]
  • Casper RF, Mitwally MFM 2006 Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 91:760–771 [PubMed]
  • Raman JD, Schlegel PN 2002 Aromatase inhibitors for male infertility. J Urol 167:624–629 [PubMed]
  • Reiter EO, Norjavaara E 2005 Testotoxicosis: current viewpoint. Pediatr Endocrinol Rev 3:77–86 [PubMed]
  • Kreher NC, Pescovits OH, Delameter P, Tiulpakov A, Hochberg Z 2006 Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. J Pediatr 149:416–420 [PubMed]
  • Karmazin A, Moore WV, Popovic J, Jacobson JD 2005 The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function. J Pediatr Endocrinol 18:285–293 [PubMed]
  • Mauras N, Lima J, Patel D, Rini A, DiSalle E, Kwok A, Lippe B 2003 A pharmacokinetics and dose finding of a potent aromatase inhibitor, Aromasinâ (Exemestane) in young males. J Clin Endocrinol 88:5951–5956 [PubMed]
  • Hero M, Wickman S, Dunkel L 2006 Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf) 64:510–513 [PubMed]

Articles from The Journal of Clinical Endocrinology and Metabolism are provided here courtesy of The Endocrine Society
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...